PIK3CA and cancer: In vitro pharmacologic sensitivity screen among a broad panel of cancer cell lines revealed that sensitivity to alpelisib was positively associated with the presence of PIK3CA mutation, amplification or copy number gain [84], which was confirmed by an in vivo study using mouse models [52].